Pazopanib Hydrochloride in Treating Patients With Advanced or Refractory Solid Tumors

PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 19, 2012

Primary Completion Date

December 31, 2015

Study Completion Date

March 19, 2026

Conditions

Solid Neoplasm

Interventions

OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Pazopanib Hydrochloride

Given PO

OTHER

Pharmacological Study

Correlative studies

Trial Locations (2)

Mayo Clinic in Rochester, Rochester

Mayo Clinic in Florida, Jacksonville

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH